Nateglinide
Active ingredient: Nateglinide
In short: Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
What is Nateglinide used for?
Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use: Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Nateglinide dosage
The recommended dose of nateglinide tablets is 120 mg orally three times daily before meals.
The recommended dose of nateglinide tablets is 60 mg orally three times daily before meals in patients who are near glycemic goal when treatment is initiated.
Instruct patients to take nateglinide tablets 1 to 30 minutes before meals.
In patients who skip meals, instruct patients to skip the scheduled dose of nateglinide tablets to reduce the risk of hypoglycemia .
How to take Nateglinide — instructions & advice from the label
Administration
Instruct patients to take nateglinide 1 to 30 minutes before meals. Instruct patients that skip meals to skip their dose of nateglinide .
Hypoglycemia
Inform patients that nateglinide can cause hypoglycemia and instruct patients and their caregivers on self-management procedures including glucose monitoring and management of hypoglycemia. Inform patients that their ability to concentrate and react may be impaired as a result of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended .
Lactation
Advise patients that use of nateglinide is not recommended while breastfeeding .
Drug Interactions
Discuss potential drug interactions with patients and inform them of potential drug-drug interactions with nateglinide.
Rx only
Manufactured by:
Dr. Reddy’s Laboratories Limited
Bachupally – 500 090 INDIA
Revised: 1121
Warnings & precautions
Do not take this medicine if: Nateglinide is contraindicated in patients with a history of hypersensitivity to nateglinide tablets or its inactive ingredients.
All glinides, including nateglinide, can cause hypoglycemia . Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).
Hypoglycemia can happen suddenly and symptoms may differ in each individual and change over time in the same individual. Symptomatic awareness of hypoglycemia may be less pronounced in patients with longstanding diabetes, in patients with diabetic neuropathy (nerve disease), in patients using medications that block the sympathetic nervous system (e.g., beta-blockers) , or in patients who experience recurrent hypoglycemia.
Factors which may increase the risk of hypoglycemia include changes in meal pattern (e.g., macronutrient content), changes in level of physical activity, changes to coadministered medication , and concomitant use with other antidiabetic agents. Patients with renal or hepatic impairment may be at higher risk of hypoglycemia .
Patients should take nateglinide before meals and be instructed to skip the dose of nateglinide if a meal is skipped . Patients and caregivers must be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia. In patients at higher risk for hypoglycemia and patients who have reduced symptomatic awareness of hypoglycemia, increased frequency of blood glucose monitoring is recommended.
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with nateglinide.
Nateglinide side effects
The following serious adverse reaction is also described elsewhere in the labeling:
Hypoglycemia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials, approximately 2,600 patients with type 2 diabetes mellitus were treated with nateglinide. Of these, approximately 1,335 patients were treated for 6 months or longer and approximately 190 patients for one year or longer. Table 1 shows the most common adverse reactions associated with nateglinide.
Table 1: Adverse Reactions other than Hypoglycemia (%) occurring
Greater than or equal to
2% in Nateglinide-Treated Patients from Pool of 12 to 64 week Placebo Controlled Trials
Placebo
N=458 | Nateglinide
N=1441
Preferred Term
Upper Respiratory Infection | 8.1 | 10.5
Back Pain | 3.7 | 4
Flu Symptoms | 2.6 | 3.6
Dizziness | 2.2 | 3.6
Arthropathy | 2.2 | 3.3
Diarrhea | 3.1 | 3.2
Accidental Trauma | 1.7 | 2.9
Bronchitis | 2.6 | 2.7
Coughing | 2.2 | 2.4
Hypoglycemia
Episodes of severe hypoglycemia (plasma glucose less than 36 mg/dL) were reported in two patients treated with nateglinide. Non-severe hypoglycemia occurred in 2.4 % of nateglinide treated patients and 0.4 % of placebo treated patients . …
Drug interactions
Table 2 includes a list of drugs with clinically important drug interactions when concomitantly administered or withdrawn with nateglinide and instructions for managing or preventing them.
Table 2: Clinically Significant Drug Interactions with Nateglinide
Drugs That May Increase the Blood-Glucose-Lowering Effect of
Nateglinide and Susceptibility to Hypoglycemia
Drugs: | Nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g. methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g. amiodarone, fluconazole, voriconazole, sulfinpyrazone), or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol.
Intervention: | Dose reductions and increased frequency of glucose monitoring may be required when nateglinide is coadministered with these drugs.
Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of
Nateglinide and Increase Susceptibility to Hyperglycemia
Drugs: | Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g. lanreotide, octreotide), and CYP inducers (e.g. rifampin, phenytoin and St John’s Wort). …
About this medicine
Nateglinide is an oral blood glucose-lowering drug of the glinide class. Nateglinide, (-)-N-[(trans-4-isopropylcyclohexane)carbonyl]-D-phenylalanine, is structurally unrelated to the oral sulfonylurea insulin secretagogues.
The structural formula is as shown:
Nateglinide is an off-white to white powder with a molecular weight of 317.43 g/mol. It is freely soluble in methanol, ethanol, and chloroform, soluble in ether, sparingly soluble in acetonitrile and octanol, and practically insoluble in water. Nateglinide biconvex tablets contain 60 mg, or 120 mg, of nateglinide for oral administration.
Inactive Ingredients: carnauba wax, copovidone, croscarmellose sodium, mannitol, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate, corn starch and talc.
How it works: Nateglinide lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets. Nateglinide interacts with the ATP-sensitive potassium (K+ATP) channel on pancreatic beta-cells.
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f7b28951-76d2-cabd-64a1-b74aa225c6e9. Read the full official label on DailyMed.
Related medicines
Atorvastatin Metformin Losartan Semaglutide Insulin Glargine Empagliflozin Glipizide Insulin Lispro